From: Effect of duloxetine in patients with fibromyalgia: tiredness subgroups
P-value (treatment-by-tiredness subgroup) | Mild subgroup | Moderate subgroup | Severe subgroup | ||||
---|---|---|---|---|---|---|---|
Placebo (n = 20) (%) | Duloxetine (n = 29) (%) | Placebo (n = 83) (%) | Duloxetine (n = 133) (%) | Placebo (n = 430) (%) | Duloxetine (n = 634) (%) | ||
Patients with ≥1 TEAE | 0.040 | 90.0 | 96.6 | 73.5 | 91.0 | 77.7 | 82.0 |
Hypoaesthesia | 0.094 | 10.0 | 0.0 | 1.2 | 1.5 | 1.2 | 2.1 |
Arthralgia | 0.008 | 10.0 | 0.0 | 9.6 | 2.3 | 2.8 | 3.8 |
Cough | 0.034 | 15.0 | 0.0 | 1.2 | 3.0 | 2.6 | 3.2 |
Myalgia | 0.081 | 10.0 | 3.5 | 0.0 | 3.8 | 1.6 | 3.3 |
Bronchitis | 0.014 | 5.0 | 0.0 | 3.6 | 0.0 | 2.3 | 3.3 |
Influenza | 0.019 | 0.0 | 3.5 | 6.0 | 0.8 | 1.4 | 2.5 |
Palpitations | 0.085 | 0.0 | 3.5 | 4.8 | 1.5 | 2.5 | 1.2 |
Restless leg syndrome | 0.030 | 5.0 | 0.0 | 0.0 | 3.0 | 1.4 | 0.6 |
Osteoarthritis | 0.029 | 10.0 | 0.0 | 3.6 | 0.0 | 0.7 | 0.8 |